Lantheus has inked a deal giving GE HealthCare the rights to carry its prostate cancer PET imaging agent in Japan, with the ...

While the average earnout potential per biopharma deal has declined over the last five years, the mean upfront value has been ...

Sparrow Pharmaceuticals is looking to send its potential diabetes treatment soaring through clinical trials with the help of ...

Heartflow has secured a new FDA clearance for its artificial intelligence program to analyze the buildup of dangerous plaques ...

When it comes to Cyclerion Therapeutics' colorful backstory, the only consistency has been its inconsistency. | When it comes ...

Glooko is looking to expand its diabetes treatment platforms to the inpatient setting, with a plan to acquire Monarch Medical ...

Medtronic has announced plans to double the footprint of its London office, focused on developing artificial intelligence and ...

Pfizer has thrown money at its obesity R&D problem. Having seen its internal assets flounder, the Big Pharma has struck a ...

The New York Stock Exchange helped ring in this year’s Fierce 15 by honoring the winners on the trading floor Monday morning.

Of the 54 patients enrolled in a phase 1-3 trial, those given zilganersen could walk an average of 33.3% faster compared with ...

PacBio aims to dive deeper into the family planning market with an updated carrier screening kit designed to take multiple ...

Angelini Pharma has worked out a $550 million-plus biobucks deal to get its hands on a Korean biotech’s preclinical neuro ...